BioSpace News Archive

Urologists at Hackensack University Medical Center have become the first in northern New Jersey to offer an innovative treatment for benign prostatic hyperplasia that uses a high-intensity waterjet to destroy excess prostate tissue that causes uncomfortable urinary symptoms for many older men.

Each year, more than 48 million cases of sepsis are diagnosed and account for 11 million deaths annually.

Ventyx Biosciences, Inc. announced that Company executives will host investor meetings and provide a company overview during fireside chats at the following upcoming investor conferences:

The global transcranial magnetic stimulation system market was estimated at USD 1.07 billion in 2021 and is expected to hit around USD 2.46 billion by 2030, growing at a CAGR of 9.69% from 2022 to 2030.

Conformis, Inc. announced that Mark Augusti, Chief Executive Officer, and Bob Howe, Chief Financial Officer, will participate in the H.C. Wainwright & Co. 24th Annual Global Investment Conference.

Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today provided a corporate update and reported financial results for the first half of 2022.

Atmofizer Technologies Inc. (the “Company” or “Atmofizer”) (CSE: ATMO) (Frankfurt: J3K) (OTCQB: ATMFF) is pleased to announce its financial results for the quarter ended June 30, 2022.

Coherus BioSciences, Inc., announced that effective August 24, 2022, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 234,000 shares of the common stock of the Company to 22 newly hired employees with a per share exercise price of $12.90, the closing trading price on the grant date.

According to the current analysis of Reports and Data, the global ENT Surgical Navigation Systems Market valued at USD 77.8 million in 2018 and is expected to reach USD 110.5 million by the year 2026, at a CAGR of 4.4%.

Wenzel Spine, Inc., today announced the launch of the S-LIF Procedure for Stand-alone Lumbar Interbody Fusion using the VariLift®-LX device, the only stand-alone expandable posterior lumbar interbody fusion device that is FDA-cleared for 1 or 2 level fusion.